COMP <GO>
ANRO vs AKTS // EV/EBITDA & P/E VALUATION
Alto Neuroscience Inc. (NYSE) VS. Aktis Oncology Inc. (NASDAQ) • 15-METRIC TALLY: ANRO 1
— AKTS 1
■ METRIC PARITY
LAST: $23.47 (+0.60%) • MKT CAP: $921.0M
valuation
—
LAST: $16.85 (+0.18%) • MKT CAP: $937.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANRO VS. AKTS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANRO | AKTS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.62% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.7 | 36.4 | +3.28 | ANRO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $921.0M | $937.2M | -$16.2M | AKTS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANRO REV | AKTS REV | ANRO GROSS % | AKTS GROSS % | ANRO FCF | AKTS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$51.8M | — |
| FY 2024 | $0 | — | — | — | -$49.5M | — |
| FY 2023 | $0 | — | — | — | -$33.4M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANRO // BETA —
AKTS // BETA —